Predictive Modelling of COVID-19 Patient Outcomes Using Deep Learning Techniques
DOI:
https://doi.org/10.24237/djes.2026.19107Keywords:
COVID-19 prediction, Neural networks, Transformer, ICU overflow, Patient outcome classificationAbstract
Prediction of clinical outcome in patients with COVID-19 is important for timely intervention, appropriate ICU triage, and best utilization of hospital resources. We propose a deep learning framework to predict the patient outcomes by utilizing longitudinal clinical data from a tertiary care hospital in India. After quality control (QC) preprocessing and filtering, 126,716 diagnostic records with 13 key laboratory and vital sign variables were retained for analysis. We propose and test several neural architectures for the classification of ICU vs ward patients, namely GRU, LSTM, BiLSTM, CNN-LSTM, and Transformer models. A two-stage experimental setup was employed. We began by doing an exploratory train-test analysis for hyperparameter tuning. Next, we performed a rigorous comparative analysis based on the five-fold cross-validation results. We evaluated the performance according to such criteria as accuracy, sensitivity, specificity, recall, precision, F1-score, ROC curve and AUC. Of the models we tested, the Transformer performs best overall, with 91.9% accuracy, 85.4% sensitivity, 75.6% specificity, and 83.1% recall. It clearly demonstrates a good specificity in the view of high-risk patients, but with a minimum false negative rate. The CNN-LSTM had a comparably good performance and the GRU was an attractive low-cost alternative with reasonable predictive power and computational burden. The generalizability of our models was validated externally, where the Transformer also yielded the best performance on unseen clinical data. These results highlight the promise of deep learning, in particular Transformer-based models, as robust instruments for COVID-19 prognosis and ICU admission management.
Downloads
References
[1] J. Y. Lee, H. J. Kim, S. H. Park, S. J. Choi, S. H. Kim, S. J. Yeo, S. H. Park, H. Lee, J. H. Park, S. S. Lee, and S. H. Kim, “A risk scoring system to predict progression to severe pneumonia in patients with COVID-19,” Sci. Rep., vol. 12, p. 5390, 2022. doi: 10.1038/s41598-022-07610-9
[2] J. J. M. Wong, H. L. Tan, J. H. Lee, R. L. H. Low, S. S. Mohamad, J. H. Lee, and K. C. Thoon, “Development and validation of a clinical predictive model for severe and critical pediatric COVID-19 infection,” PLoS ONE, vol. 17, p. e0275761, 2022. doi: 10.1371/journal.pone.0275761
[3] G. Li, K. Chen, and H. Yang, “A new hybrid prediction model of cumulative COVID-19 confirmed data,” Process Saf. Environ. Prot., vol. 157, pp. 1–19, 2022. doi: 10.1016/j.psep.2021.10.047
[4] G. Li, R. Hilgenfeld, R. Whitley, and E. De Clercq, “Therapeutic strategies for COVID-19: progress and lessons learned,” Nat. Rev. Drug Discov., vol. 22, pp. 449–475, 2023. doi: 10.1038/s41573-023-00672-w
[5] L. Chi, S. Wang, X. Wang, Q. Wu, S. Ge, and X. Gu, “Predictive value of C-reactive protein for disease severity and survival in COVID-19 patients: A systematic review and meta-analysis,” Clin. Exp. Med., vol. 23, pp. 2001–2008, 2023. doi: 10.1007/s10238-022-00948-4
[6] F. P. Esper, T. M. Adhikari, Z. J. Tu, G. Cheng, K. J. El-Haddad, R. Hashmi, and S. S. Richter, “Alpha to Omicron: Disease severity and clinical outcomes of major SARS-CoV-2 variants,” J. Infect. Dis., vol. 227, pp. 344–352, 2023. doi: 10.1093/infdis/jiac411
[7] P. Irizar, T. Chen, O. Doyle, C. Simpson, L. J. Gray, K. Khunti, and M. G. Katikireddi, “Ethnic inequalities in COVID-19 infection, hospitalisation, intensive care admission, and death: A global systematic review and meta-analysis of over 200 million study participants,” EClinicalMedicine, vol. 57, p. 101877, 2023. doi: 10.1016/j.eclinm.2023.101877
[8] W. K. Loo, W. Voon, A. Suhaimi, M. R. Abdul-Rashid, and N. S. Azman, “Predictive modeling of COVID-19 readmissions: Insights from machine learning and deep learning approaches,” Diagnostics, vol. 14, no. 14, p. 1511, 2024. doi: 10.3390/diagnostics14141511
[9] S. Azekawa, H. Nakamura, T. Yamaguchi, K. Katsurada, M. Namiki, and Y. Kaneko, “Serum KL-6 levels predict clinical outcomes and are associated with MUC1 polymorphism in Japanese patients with COVID-19,” BMJ Open Respir. Res., vol. 10, p. e001625, 2023. doi: 10.1136/bmjrespc-2023-001625
[10] H. Lee, T. Saito, J. Nakamura, R. Kondoh, T. Sano, H. Terada, and K. Tanimoto, “Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: A report from the Japan COVID-19 Task Force,” BMC Infect. Dis., vol. 22, p. 935, 2022. doi: 10.1186/s12879-022-07927-w
[11] S. Otake, T. Fujita, Y. Inoue, K. Sano, M. Hirayama, and T. Kanai, “Clinical clustering with prognostic implications in Japanese COVID-19 patients: Report from Japan COVID-19 Task Force, a nation-wide consortium to investigate COVID-19 host genetics,” BMC Infect. Dis., vol. 22, p. 735, 2022. doi: 10.1186/s12879-022-07701-y
[12] P. Charilaou and R. Battat, “Machine learning models and over-fitting considerations,” World J. Gastroenterol., vol. 28, pp. 605–607, 2022. doi: 10.3748/wjg.v28.i5.605
[13] L. Luo, P. Gao, C. Yang, S. Wu, J. Zhang, and H. Wang, “Predictive modeling of COVID-19 mortality risk in chronic kidney disease patients using multiple machine learning algorithms,” Sci. Rep., vol. 14, p. 26979, 2024. doi: 10.1038/s41598-024-78498-w
[14] K. Kojima, H. Yoon, K. Okishio, and K. Tsuyuguchi, “Increased lactate dehydrogenase reflects the progression of COVID-19 pneumonia on chest computed tomography and predicts subsequent severe disease,” Sci. Rep., vol. 13, p. 1012, 2023. doi: 10.1038/s41598-023-28201-2
[15] S. Nojiri, Y. Irie, R. Kanamori, T. Miyashita, K. Ogawa, and K. Ito, “Mortality prediction of COVID-19 in hospitalized patients using the 2020 diagnosis procedure combination administrative database of Japan,” Intern. Med., vol. 62, pp. 201–213, 2023. doi: 10.2169/internalmedicine.0086-22
[16] N. Dave, M. Patel, R. Shah, S. Gupta, and V. Mehta, “Nosocomial SARS-CoV-2 infections and mortality during unique COVID-19 epidemic waves,” JAMA Netw. Open, vol. 6, p. e2341936, 2023. doi: 10.1001/jamanetworkopen.2023.41936
[17] T. Ozawa, S. Chubachi, H. Namkoong, K. Sato, Y. Katsuta, S. Azekawa, and N. Hasegawa, “Predicting coronavirus disease 2019 severity using explainable artificial intelligence techniques,” Sci. Rep., vol. 15, p. 9459, 2025. doi: 10.1038/s41598-025-85733-5
[18] R. Soundrapandiyan, A. Manickam, M. Akhloufi, and K. S. Sivaraman, “An efficient COVID-19 mortality risk prediction model using deep synthetic minority oversampling technique and convolution neural networks,” BioMedInformatics, vol. 3, pp. 339–368, 2023. doi: 10.3390/biomedinformatics3020023
[19] N. M. Elshennawy, D. M. Ibrahim, A. M. Sarhan, and M. Arafa, “Deep-Risk: Deep learning-based mortality risk predictive models for COVID-19,” Diagnostics, vol. 12, p. 1847, 2022. doi: 10.3390/diagnostics12081847
[20] G. S. Gupta, “The lactate and the lactate dehydrogenase in inflammatory diseases and major risk factors in COVID-19 patients,” Inflammation, vol. 45, pp. 2091–2123, 2022. doi: 10.1007/s10753-022-01680-7
[21] M. B. Long, Y. Chen, L. Zhou, S. Tang, J. Zhao, and Y. Wang, “Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection,” Eur. Respir. J., vol. 63, p. 2300787, 2024. doi: 10.1183/13993003.00787-2023
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Kalaiselvi K, Bairavel S, S. Sumathi, Kanipriya M, Anitha Govindaram, Jose Anand A

This work is licensed under a Creative Commons Attribution 4.0 International License.









